Skip to main content
. 2020 Jun 22;130(8):4039–4054. doi: 10.1172/JCI135105

Figure 9. Complement activation and factor H in human HCC.

Figure 9

(A) iC3b/C3d and GPC3 deposition in human HCC biopsies. Scale bars: 50 μm (left panels), 20 μm (right panels); n = 6. (B and C) Kaplan-Meier plots and statistical analysis based on the work of the TCGA Firehose Legacy study, showing the effect of increased CFH mRNA expression (B) and CFH mutations (C) within the tumors of HCC patients, on survival and disease progression. Increased tumor-associated CFH mRNA improved both progression-free survival (B, top, **P = 0.0020; n = 18 relapse out of 45 [high CFH mRNA], 161 out of 280 [unaltered]) and overall survival (B, bottom: *P = 0.0265; n = 11 deceased out of 50 [high CFH mRNA] and 121 out of 326 [unaltered]). Tumor-associated CFH mutations reduced the number of disease/progression-free months (C, top: P = 0.0778; n = 4 relapsed/progressed out of 5 [CFH mutation] and 175 out of 320 [unaltered]) and overall survival (C, bottom: *P = 0.0308; n = 4 deceased out of 7 [CFH mutation] and 128 out of 369 [unaltered]). Median months survival and progression-free survival shown in parentheses for each group. Data were analyzed by log rank Mantel-Cox test.